These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 18607393)

  • 21. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.
    Pantuck AJ; Thomas G; Belldegrun AS; Figlin RA
    Semin Oncol; 2006 Oct; 33(5):607-13. PubMed ID: 17045090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinase inhibitors in the treatment of renal cell carcinoma.
    Larkin JM; Eisen T
    Crit Rev Oncol Hematol; 2006 Dec; 60(3):216-26. PubMed ID: 16860997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temsirolimus: a safety and efficacy review.
    Bukowski RM
    Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
    Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
    Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
    J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
    Mounier N; Vignot S; Spano JP
    Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving outcomes in patients with advanced renal cell carcinoma.
    Sosman JA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of mTOR inhibitor side effects.
    Creel PA
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug insight: advances in renal cell carcinoma and the role of targeted therapies.
    Larkin JM; Chowdhury S; Gore ME
    Nat Clin Pract Oncol; 2007 Aug; 4(8):470-9. PubMed ID: 17657252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M; Douis H; Porfiri E
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
    [No Abstract]   [Full Text] [Related]  

  • 37. Temsirolimus for advanced renal cell carcinoma.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
    [No Abstract]   [Full Text] [Related]  

  • 38. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
    Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
    Armstrong AJ; George DJ; Halabi S
    J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.